A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia - Tantravahi, S K; Szankasi, P; Khorashad, J S (Leuk Lymphoma, 2016)